Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 5/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6339246 | 0.84 | MAOB (0.51) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL6347648 | 0.84 | MAOB (0.64) | MAOBEGFRNR4A1NR4A2NR4A3 | |
| SCHEMBL6341711 | 0.84 | NR4A2 (0.62) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL1034311 | 0.83 | MAOB (0.63) | MAOBEGFRNR4A1NR4A2NR4A3 | |
| SCHEMBL6337027 | 0.81 | ACACB (0.50) | MAOBEGFRNR4A1NR4A2NR4A3 | |
| SCHEMBL6703917 | 0.79 | NR4A2 (0.70) | MAOBEGFRNR4A1NR4A2NR4A3 | |
| SCHEMBL31081572 | 0.78 | CXCR2 (0.50) | MAOBEGFR | |
| SCHEMBL6347392 | 0.76 | FFAR1 (0.50) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL20103340 | 0.74 | KMT2A (0.49) | MAOBNR4A2 | |
| SCHEMBL6348703 | 0.73 | PPARG (0.42) | MAOBEGFRNR4A1NR4A2NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6890932-B2 | Immunoglobulin e antibody suppressors | TEIJIN LIMITED (JP) | 2005-05-10 | — | — | US | disclosed |
| EP-1101755-B1 | ANTHRANILIC ACID DERIVATIVES | TEIJIN LTD (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-20030232811-A1 | Immunoglobulin e antibody suppressors | TEIJIN LIMITED | 2003-12-18 | — | — | US | disclosed |
| US-6649656-B1 | Anticarcinogenic, antiallergen, antishock, and antiasthmatic agents | TEIJIN LIMITED (JP) | 2003-11-18 | — | — | US | disclosed |
| EP-1101755-A1 | ANTHRANILIC ACID DERIVATIVES | TEIJIN LIMITED (JP) | 2001-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232811-A1 | Immunoglobulin e antibody suppressors | IGLV6-57, FCGRT, IGSF11 | MAOB 2681/4885EGFR 1011/4885NR4A1 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.